

SUPPLEMENTAL DATA

Mechanisms of resistance to EGFR inhibition reveal metabolic vulnerabilities in human GBM

Andrew McKinney¹, Olle R. Lindberg¹, Jane R. Engler¹, Katharine Y. Chen¹, Anupam Kumar¹, Henry Gong¹, Kan V. Lu¹, Erin F. Simonds^{1,2}, Timothy F. Cloughesy^{3,4}, Linda M. Liao^{3,5}, Michael Prados¹, Andrew W. Bollen⁶, Mitchel S. Berger¹, Joseph T.C. Shieh^{7,8}, C. David James⁹, Theodore P. Nicolaides^{1,10}, William H. Yong¹¹, Albert Lai^{3,4}, Monika E. Hegi¹², William A. Weiss^{1,2,10}, Joanna J. Phillips^{1,6}.

Supplemental Figure S1. Inhibition of PI3K or Src activation does not confer increased tumor cell invasion. (A-B) Inhibition of activation of PI3K (LY294002) or Src (50nM dasatinib) did not increase invasion of GPCs in 3D spheroid invasion assays. **(C-D)** Western blots demonstrating inhibition of phosphorylation of Akt and Src at 16 hours after addition of LY294002 or dasatinib, respectively. **(E)** Decreased tumor cell proliferation upon EGFR inhibition. **(F)** Gene expression of ALDH1A1 in cells resistant to EGFR inhibition with erlotinib (Erl), AG1478, or lapatinib relative to control treated cells. **(G)** Gene expression of CXCR4, S100A4, TIMP3, EPHA4, NTRK2, CNTN1, and GAB1 in CSCs resistant to EGFR inhibition relative to control treated CSCs. Representative images and quantification, mean \pm SEM (n=3) performed twice, n.s., not significant. Scale bar = 100 μ m. ****p<0.0001, ***p<0.001, **p<0.01.

